LRP5 and breast cancer: CCK8 assay showed that NaBu treatment (2 mM or 4 mM) had little effect on cell viability of breast cancer (Supplementary Fig. 6b), while dose-dependently inhibited LRP5 mRNA level (Fig. 4e and Supplementary Fig. 6c).